News from biotrends research group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 19, 2013, 10:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Although Physicians' Overall Impressions on the Dialysis Bundle are More Positive, Cost Concerns Remain High, Especially as Dialysis Units Prepare for Continued Changes

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in Q4 2013...

Dec 19, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

Dec 12, 2013, 10:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Dec 10, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Dec 09, 2013, 12:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12...

Dec 09, 2013, 10:23 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At One Month Post-Launch, More than One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Boehringer Ingelheim's Gilotrif for Non-Small-Cell Lung Cancer

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one...

Dec 03, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Most Rheumatologists Believe that a Steroid-Sparing Effect Would Be an Important Benefit of a New Drug for Systemic Lupus Erythematosus (SLE)

BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 80 percent...

Dec 02, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

Nov 26, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

Nov 25, 2013, 11:29 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Nov 21, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

Oct 31, 2013, 10:20 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among...

Oct 31, 2013, 08:00 ET

The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed...

Oct 30, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis

 BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...

Oct 30, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, while...

Oct 23, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Humira and Simponi Have Been Prescribed By Significantly More U.S. Gastroenterologists in 2013 than in 2012, Likely Owing to Their Recent Approvals for Ulcerative Colitis

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds...

Oct 22, 2013, 11:43 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one...

Oct 17, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Nearly Half of Surveyed European Retinal Specialists Currently Treat Wet AMD Patients with Bayer's Eylea Eight Months after Its Approval

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, eight...

Oct 16, 2013, 08:00 ET

Endocrinologists Would Prefer Extensive Efficacy Data Before Prescribing Biosimilar Insulins

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S....

Oct 01, 2013, 09:56 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among...